Table 2.
Risk factors for hypersensitivity reaction
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| Age (years) | 1.03 (0.99–1.06) | 0.13 | 1.03 (0.99–1.06) | 0.15 |
| Female | 0.65 (0.32–1.32) | 0.24 | ||
| Body surface area ≥1.57 m2 | 1.79 (0.89–3.60) | 0.11 | 2.18 (1.02–4.65) | 0.045 |
| Skin disease career | 0.41 (0.052–3.28) | 0.40 | ||
| Allergic history | 0.72 (0.32–1.61) | 0.43 | ||
| Platinum allergic history | 5.50 (1.07–28.33) | 0.042 | 4.97 (0.82–30.06) | 0.081 |
| Medical history with L-OHP | 1.91 (0.89–4.10) | 0.10 | 1.58 (0.64–3.94) | 0.33 |
| Metastasis | 2.02 (0.80–5.09) | 0.14 | 1.38 (0.50–3.79) | 0.54 |
| mFOLFOX6 therapy | 0.68 (0.34–1.36) | 0.28 | ||
| L-OHP dosage (mg/m2/cycle) | 1.00 (0.99–1.02) | 0.60 | ||
| L-OHP cumulative dosage (mg/m2) | 1.00 (1.00–1.00) | 0.29 | ||
| L-OHP cumulative dosage (mg) | 1.00 (1.00–1.00) | 0.16 | 1.00 (1.00–1.00) | 0.61 |
| Bmab | 1.77 (0.89–3.52) | 0.11 | 1.64 (0.77–3.49) | 0.20 |
| Pmab | 1.31 (0.35–4.89) | 0.69 | ||
| Steroid administered with L-OHP at the same time | 0.80 (0.38–1.71) | 0.57 | ||
| Dex dosage (mg/cycle) | 1.00 (0.55–1.81) | 1.00 | ||
| Pre-medication with steroid except Dex | 1.28 (0.49–3.36) | 0.62 | ||
| Albumin (g/dL) | 0.77 (0.46–1.28) | 0.30 | ||
| AST (IU/L) | 1.00 (1.00–1.01) | 0.12 | 1.00 (1.00–1.01) | 0.59 |
| ALT (IU/L) | 1.01 (1.00–1.01) | 0.14 | 1.00 (1.00–1.01) | 0.42 |
| Scr (mg/dL) | 1.13 (0.23–5.61) | 0.89 | ||
| eGFR (mL/min/1.73 m2) | 1.00 (0.98–1.01) | 0.62 | ||
Risk factors are analysed with multivariable logistic regression models
L-OHP oxaliplatin, Bmab bevacizumab, Pmab panitumumab, Dex dexamethasone, AST aspartate aminotransferase, ALT alanine aminotransferase, Scr creatinine, eGFR estimated glomerular filtration rate
Hosmer–Lemeshow test, P = 0.62